I’m a weight-loss doctor — the unusual complication I’m seeing from Ozempic-like drugs
A top NYC weight-loss doctor shared the surprising skin complication that he’s encountered in patients using GLP-1 drugs like Ozempic.
"They're not shortcuts": How weight loss drugs became the business of shame
The use of GLP-1 drugs sparked the term "Ozempic shaming" to describe the negative perceptions faced by those who choose medical interventions for weight management. Some critics argue that using the drugs is akin to "taking a shortcut," overlooking the complex factors that contribute to obesity.
How do GLP-1 drugs work for weight loss?
Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame themselves for it.
Less than 50% of employers cover GLP-1 drugs for weight loss: JPM survey
"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated that almost 50 million adults in employer plans meet the clinical criteria for taking such drugs, which can cost thousands of dollars annually per person," according to a report from Kaiser Family Health (KFF) in October.
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
Rise of weight-loss drugs may rebalance grocery scales
Researchers documented a six per cent to nine per cent decline in grocery spending within the first six months of the GLP-1 drug use driven by “significantly larger” decreases in purchases of calorie-dense processed items, including an 11 per cent decline in savoury snacks.
Some GLP-1s Achieve More Weight Loss Than Others: Study
We found that, of the 12 GLP-1 (drugs) identified by our search, the greatest mean body weight reduction was reported in randomized controlled trials of retatrutide, tirzepatid
Two years on, are GLP-1 drugs such as Ozempic and Mounjaro here to stay?
In January 2023, the world was abuzz with stories of a revolutionary weight-loss drug – a simple, self-administered injection that promised to transform the lives of those struggling with obesity. The click-baity headlines surrounding Ozempic,
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.
Medscape4d
Early Intervention Central to Treating Muscle Mass Loss in Patients Losing Weight With GLP-1 Meds
Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...
TCTMD1d
Variety of GLP-1 Drugs Help People Without Diabetes Lose Weight: Review
With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
LifeVantage: Bold Move Into The GLP-1 Weight Loss Market Turns Out To Be A Major Winner - Buy
LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...
High-cost weight loss drugs are sending employers to nutrition counseling in a boost for startups
Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...
As demand for weight-loss drugs rises, states grapple with Medicaid coverage
Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...
Weight-loss drug developer Metsera reveals wider loss in US IPO filing
(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a ...
Gemma Collins says she 'will finally be free' thanks to weight-loss 'transformation'
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...